CCX 025

Drug Profile

CCX 025

Alternative Names: CCR9 2G; CCX025

Latest Information Update: 10 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemoCentryx
  • Class Anti-inflammatories; Antiulcers; Small molecules
  • Mechanism of Action CCR9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gastrointestinal disorders

Most Recent Events

  • 10 Dec 2013 No development reported - Phase-I for Gastrointestinal disorders in USA (PO)
  • 20 Apr 2011 Clinical development is ongoing in USA
  • 15 Oct 2008 Phase-I clinical trials in Gastrointestinal disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top